Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients.

Abstract

Twenty ALS patients with sialorrhea refractory to medical therapy were enrolled in this double-blind, randomized study to receive either 2,500 U of botulinum toxin type B (BTxb) or placebo into the bilateral parotid and submandibular glands using electromyographic guidance. Patients who received BTxb reported a global impression of improvement of 82% at 2 weeks compared to 38% of those who received placebo (P < 0.05). This significant effect was sustained at 4 weeks. At 12 weeks, 50% of patients who received BTxb continued to report improvement compared to 14% of those who received placebo. There were no significant adverse events, including dysphagia, in the BTxb group, and there was no significant increase in the rate of decline of vital capacity.

• Authors: Carlayne E Jackson, Gary Gronseth, Jeffrey Rosenfeld, Richard J Barohn, Richard Dubinsky, C Blake Simpson, April McVey, Pamela P Kittrell, Ruth King, Laura Herbelin, Muscle Study Group
• Journal: Muscle & nerve (Muscle Nerve) Vol. 39 Issue 2 Pg. 137-43 (Feb 2009) ISSN: 0148-639X [Print] United States
• PMID: 19145653 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Dyskinesia Agents
• rimabotulinumtoxinB
• Botulinum Toxins
• Botulinum Toxins, Type A

Topics

• Adult
• Aged
• Aged, 80 and over
• Amyotrophic Lateral Sclerosis (complications)
• Anti-Dyskinesia Agents (therapeutic use)
• Botulinum Toxins (therapeutic use)
• Botulinum Toxins, Type A
• Double-Blind Method
• Female
• Humans
• Male
• Middle Aged
• Severity of Illness Index
• Sialorrhea (drug therapy, etiology)
• Time Factors
• Young Adult